EWA
MRNA icon

EP Wealth Advisors’s Moderna MRNA Stock Holding History

EP Wealth Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
+4,641
New +$240K ﹤0.01% 1243
2024
Q2 		– Sell
-2,385
Closed -$254K – 880
2024
Q1 		$254K Buy
+2,385
New +$240K ﹤0.01% 672
2023
Q4 		– Sell
-3,241
Closed -$335K – 829
2023
Q3 		$335K Buy
3,241
+2,007
+163% +$224K 0.01% 538
2023
Q2 		$387K Sell
1,234
-130,446
-99% -$17.4M 0.01% 513
2023
Q1 		$14M Buy
131,680
+129,736
+6,674% +$21.4M 0.24% 73
2022
Q4 		$349K Buy
+1,944
New +$318K 0.01% 436
2022
Q3 		– Sell
-1,930
Closed -$276K – 519
2022
Q2 		$276K Buy
1,930
+472
+32% +$67.5K 0.01% 496
2022
Q1 		$251K Sell
1,458
-314
-18% -$52.9K 0.01% 521
2021
Q4 		$450K Buy
1,772
+61
+4% +$17.8K 0.01% 375
2021
Q3 		$658K Buy
1,711
+60
+4% +$22.1K 0.02% 293
2021
Q2 		$388K Buy
+1,651
New +$295K 0.01% 385

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

EP Wealth Advisors's MRNA Position: Q2 2026 in Review

EP Wealth Advisors opened a new position in Moderna (MRNA) in Q2 2026: 4,641 shares worth $325K. The stake represents ﹤0.01% of the portfolio and ranks #1243 among its holdings. This is a return to the name: EP Wealth Advisors previously reported a position in MRNA as recently as Q1 2024.

EP Wealth Advisors first reported a position in MRNA in Q2 2021 and has held it in 11 quarters since. The position peaked at $14M in Q1 2023. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • EP Wealth Advisors held 4,641 shares of Moderna worth $325K as of Q2 2026.
  • Moderna was a new EP Wealth Advisors position in Q2 2026.
  • Moderna made up ﹤0.01% of EP Wealth Advisors's portfolio in Q2 2026, its #1243 holding.
  • EP Wealth Advisors first reported a position in Moderna in Q2 2021 and has held it in 11 quarters since.
  • EP Wealth Advisors's Moderna position peaked at $14M in Q1 2023.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on EP Wealth Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.